Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2011. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the transaction price of 1396.06 pence per share for a specific share purchase.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a specific increase in shareholding by a connected person.
Management Commentary and Risks
The filing discloses that Mrs. K Thomson, a connected person to Director Mr. P C Thomson, acquired 19,100 ordinary shares on October 11, 2011. This transaction resulted from the re-investment of the dividend paid to shareholders on October 6, 2011. The company was advised of this transaction on October 12, 2011, in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Investor Verification Points
- Verify the total number of shares held by Mrs. K Thomson following this transaction.
- Confirm the dividend amount per share paid on October 6, 2011, to validate the reinvestment calculation.
- Review the company's full annual or interim financial reports for comprehensive performance metrics not included in this 6-K.